Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing
UF Innovate | Accelerate graduate Oragenics, Inc., a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, announced its lead candidate for treating concussion successfully completed a study that indicates ONP-002 does not cause cardiotoxicity.
Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
Oragenics, Inc., a UF Innovate | Accelerate alumnus company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, announced it has completed a prototype of its automated intranasal device for use in concussed patients who are initially confused, dazed or unconscious in the acute phase of injury.
Oragenics CEO Stepping Down
UF Innovate | Accelerate Sid Martin graduate company Oragenics announced on Monday that their CEO, Kimberly Murphy, would be stepping down. Murphy and the company said they had come to a mutual separation agreement. The board appointed Michael Redmond, company president, as interim "principal executive officer".
Murphy served as CEO since June 2022, and the company said the decision was not the result of a disagreement. She has been on the board for Oragenics since 2020 and previously served as vice president of GSK, where she helped develop vaccines for influenza and shingles.
Oragenics, Inc. Announces Private Placement
Oragenics, a UF startup, is partnering with healthcare investors. They've privately placed 404,728 shares of common stock and 404,728 shares of Series E Mirroring Preferred Stock to fight infectious diseases, including coronaviruses.
Oragenics Appoints Seasoned Vaccine Executive Kimberly Murphy as President and Chief Executive Officer
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, a biotech company dedicated to fighting infectious diseases including coronaviruses, announces the appointment of Ms. Kimberly M. Murphy, member of the Board of Directors, as President and Chief Executive Officer effective June 23, 2022. Ms. Murphy brings more than 25 years of vaccine industry experience at leading pharmaceutical companies including serving as a key leader in the successful US and Global launch of Merck’s HPV/Gardasil Franchise. Ms. Murphy joined Oragenics’ Board of Directors in 2020.
Oragenics Announces Publication of Positive Data for Its Nt-CoV2-1 Intranasal COVID-19 Vaccine Candidate in Scientific Reports
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, a biotech company dedicated to fighting infectious diseases including coronavirus, announces the publication of an article co-authored by Oragenics and collaborators at Inspirevax and the National Research Council of Canada (“NRC”) Human Health Therapeutics Research Centre in Scientific Reports, a Nature journal.
Oragenics To Participate at the World Vaccine Congress Washington 2022
Oragenics, Inc. (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including coronavirus, announced that Kimberly Murphy, a member of the Company’s Board of Directors, will attend the upcoming World Vaccine Congress Washington that will be held on April 18-22 to showcase the Company’s lead product, NT-CoV2-1, an intranasal vaccine candidate, and to pursue business development opportunities.
Oragenics Extends Collaboration To Develop Vaccines Against Future Variants of Coronaviruses
UF startup and UF Innovate | Sid Martin Biotech graduate Oragenics, Inc. announced it has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) that enables Oragenics to pursue an intranasal vaccine designed to protect against future variants of coronaviruses.
Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on Its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1
Oragenics, Inc., announced the initiation of a Good Laboratory Practice (GLP) toxicology study to evaluate the safety profile and immunogenicity of its NT-CoV2-1 vaccine
Oragenics Extends Collaboration with the National Research Council of Canada to Develop Vaccine against the Omicron Variant
Oragenics, Inc. announced it has extended a licensing and collaboration agreement with the National Research Council of Canada (NRC) that will enable Oragenics to pursue an intranasal vaccine designed to protect against the SARS-CoV-2 Omicron variant.
